Increased serum chromogranin a level after short-term proton-pump inhibitor therapy

Background: Chromogranin A (CgA) has been shown to be a useful marker in the diagnosis of neuroendocrine tumours (NETs). Enterochromaffin-like (ECL) cell hyperplasia secondary to hypergastrinemia also leads to increase of serum CgA. It's well established that medium- or long-term proton-pump inhibitor (PPI) therapy significantly increases serum CgA via hypergastrinemia, but the effect of short-term PPI treatment (as used during PPI-test) has been scarcely evaluated. Aim: To analyze the effect of short-term PPI therapy on serum CgA levels. Patients and methods: Fourteen patients with newly diagnosed erosive reflu…